Online inquiry

IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2003MR)

This product GTTS-WQ2003MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets INSR gene. The antibody can be applied in Hunter syndrome (MPS II) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000208.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3643
UniProt ID P06213
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2003MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1335MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ13468MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ10021MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ15057MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ4702MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ14648MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ14665MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ8458MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW